Cell Medica
Biotechnology - Houston, Texas, United States
Cell Medica Employees
Cell Medica Details
Cell Medica is committed to transforming the lives of patients with cancer by developing the therapeutic potential of off-the-shelf engineered T cell therapies.Our current focus endeavors to harness the natural biology of a specific subset of cytotoxic T cells, called Natural Killer T cells (NKT cells).NKT cells demonstrate several important biological differences when compared to conventional T cells, which we believe render them particularly well suited to the development of off-the-shelf chimeric antigen receptor therapies (CAR) for the treatment of patients with both solid and hematological tumors. In addition to the introduction of a CAR, we have also engineered aspects of the resulting CAR-NKT cells to further optimize their function, potency and therapeutic effect.Our innovative CAR-NKT candidates are being developed in collaboration with Baylor College of Medicine and University of North Carolina. The first CAR-NKT product is currently in Phase I clinical trials.The company's ambition is to develop a growing portfolio of CAR-NKT products to treat broad populations of patients in need, across multiple highly prevalent tumor types.Cell Medica is also exploring other innovative preclinical programs in the field of engineered T cell therapy, based on the innovative Dominant TCR platform technology developed at University College London, which we hope to progress further over time.
